Aktienkurs

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Omsetning	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT	Tianjin Pharmaceutical Da Ren Tang Group Corp Inntekt
2026e	10,96 mrd. undefined	1,65 mrd. undefined	1,73 mrd. undefined
2025e	10,00 mrd. undefined	1,34 mrd. undefined	1,46 mrd. undefined
2024e	9,12 mrd. undefined	1,08 mrd. undefined	1,21 mrd. undefined
2023	8,22 mrd. undefined	814,79 mill. undefined	986,71 mill. undefined
2022	8,25 mrd. undefined	681,08 mill. undefined	861,79 mill. undefined
2021	6,91 mrd. undefined	592,64 mill. undefined	769,14 mill. undefined
2020	6,60 mrd. undefined	587,50 mill. undefined	661,70 mill. undefined
2019	6,99 mrd. undefined	536,80 mill. undefined	625,60 mill. undefined
2018	6,36 mrd. undefined	468,00 mill. undefined	561,70 mill. undefined
2017	5,69 mrd. undefined	348,30 mill. undefined	476,10 mill. undefined
2016	6,24 mrd. undefined	295,80 mill. undefined	423,60 mill. undefined
2015	7,08 mrd. undefined	393,20 mill. undefined	451,40 mill. undefined
2014	7,09 mrd. undefined	372,50 mill. undefined	357,80 mill. undefined
2013	6,01 mrd. undefined	344,10 mill. undefined	351,80 mill. undefined
2012	5,13 mrd. undefined	268,00 mill. undefined	441,30 mill. undefined
2011	4,39 mrd. undefined	271,90 mill. undefined	247,60 mill. undefined
2010	3,47 mrd. undefined	236,80 mill. undefined	293,30 mill. undefined
2009	2,88 mrd. undefined	168,40 mill. undefined	257,80 mill. undefined
2008	2,37 mrd. undefined	92,50 mill. undefined	176,10 mill. undefined
2007	2,26 mrd. undefined	−185,70 mill. undefined	−70,00 mill. undefined
2006	2,16 mrd. undefined	−408,20 mill. undefined	−386,60 mill. undefined
2005	2,52 mrd. undefined	51,30 mill. undefined	80,80 mill. undefined
2004	2,12 mrd. undefined	73,10 mill. undefined	64,00 mill. undefined

	Omsetning	EBIT	Inntekt
2004	2,12 mrd. CNY	73,10 mill. CNY	64,00 mill. CNY
2005	2,52 mrd. CNY	51,30 mill. CNY	80,80 mill. CNY
2006	2,16 mrd. CNY	−408,20 mill. CNY	−386,60 mill. CNY
2007	2,26 mrd. CNY	−185,70 mill. CNY	−70,00 mill. CNY
2008	2,37 mrd. CNY	92,50 mill. CNY	176,10 mill. CNY
2009	2,88 mrd. CNY	168,40 mill. CNY	257,80 mill. CNY
2010	3,47 mrd. CNY	236,80 mill. CNY	293,30 mill. CNY
2011	4,39 mrd. CNY	271,90 mill. CNY	247,60 mill. CNY
2012	5,13 mrd. CNY	268,00 mill. CNY	441,30 mill. CNY
2013	6,01 mrd. CNY	344,10 mill. CNY	351,80 mill. CNY
2014	7,09 mrd. CNY	372,50 mill. CNY	357,80 mill. CNY
2015	7,08 mrd. CNY	393,20 mill. CNY	451,40 mill. CNY
2016	6,24 mrd. CNY	295,80 mill. CNY	423,60 mill. CNY
2017	5,69 mrd. CNY	348,30 mill. CNY	476,10 mill. CNY
2018	6,36 mrd. CNY	468,00 mill. CNY	561,70 mill. CNY
2019	6,99 mrd. CNY	536,80 mill. CNY	625,60 mill. CNY
2020	6,60 mrd. CNY	587,50 mill. CNY	661,70 mill. CNY
2021	6,91 mrd. CNY	592,64 mill. CNY	769,14 mill. CNY
2022	8,25 mrd. CNY	681,08 mill. CNY	861,79 mill. CNY
2023	8,22 mrd. CNY	814,79 mill. CNY	986,71 mill. CNY
2024e	9,12 mrd. CNY	1,08 mrd. CNY	1,21 mrd. CNY
2025e	10,00 mrd. CNY	1,34 mrd. CNY	1,46 mrd. CNY
2026e	10,96 mrd. CNY	1,65 mrd. CNY	1,73 mrd. CNY

Tianjin Pharmaceutical Da Ren Tang Group Corp Bruttomargin	Tianjin Pharmaceutical Da Ren Tang Group Corp Inntjeningsmargin	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT-margin	Tianjin Pharmaceutical Da Ren Tang Group Corp Inntjeningsmargin
2026e	43,66 %	15,09 %	15,80 %
2025e	43,66 %	13,36 %	14,58 %
2024e	43,66 %	11,84 %	13,24 %
2023	43,66 %	9,91 %	12,00 %
2022	39,49 %	8,26 %	10,45 %
2021	39,76 %	8,58 %	11,13 %
2020	39,07 %	8,90 %	10,02 %
2019	41,76 %	7,68 %	8,94 %
2018	41,20 %	7,36 %	8,83 %
2017	38,68 %	6,12 %	8,37 %
2016	32,27 %	4,74 %	6,79 %
2015	29,48 %	5,55 %	6,38 %
2014	30,27 %	5,26 %	5,05 %
2013	31,86 %	5,73 %	5,85 %
2012	34,12 %	5,22 %	8,60 %
2011	34,85 %	6,19 %	5,64 %
2010	37,77 %	6,82 %	8,44 %
2009	37,54 %	5,85 %	8,95 %
2008	36,93 %	3,91 %	7,45 %
2007	34,28 %	−8,22 %	−3,10 %
2006	35,01 %	−18,86 %	−17,86 %
2005	42,58 %	2,04 %	3,21 %
2004	45,13 %	3,45 %	3,02 %

	Bruttomargin	EBIT-margin	Inntjeningsmargin
2004	45,13 %	3,45 %	3,02 %
2005	42,58 %	2,04 %	3,21 %
2006	35,01 %	−18,86 %	−17,86 %
2007	34,28 %	−8,22 %	−3,10 %
2008	36,93 %	3,91 %	7,45 %
2009	37,54 %	5,85 %	8,95 %
2010	37,77 %	6,82 %	8,44 %
2011	34,85 %	6,19 %	5,64 %
2012	34,12 %	5,22 %	8,60 %
2013	31,86 %	5,73 %	5,85 %
2014	30,27 %	5,26 %	5,05 %
2015	29,48 %	5,55 %	6,38 %
2016	32,27 %	4,74 %	6,79 %
2017	38,68 %	6,12 %	8,37 %
2018	41,20 %	7,36 %	8,83 %
2019	41,76 %	7,68 %	8,94 %
2020	39,07 %	8,90 %	10,02 %
2021	39,76 %	8,58 %	11,13 %
2022	39,49 %	8,26 %	10,45 %
2023	43,66 %	9,91 %	12,00 %
2024e	43,66 %	11,84 %	13,24 %
2025e	43,66 %	13,36 %	14,58 %
2026e	43,66 %	15,09 %	15,80 %

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Omsetning per aksje	Tianjin Pharmaceutical Da Ren Tang Group Corp EBIT per aksje	Tianjin Pharmaceutical Da Ren Tang Group Corp Resultat per aksje
2026e	14,25 undefined	0 undefined	2,25 undefined
2025e	13,01 undefined	0 undefined	1,90 undefined
2024e	11,86 undefined	0 undefined	1,57 undefined
2023	10,69 undefined	1,06 undefined	1,28 undefined
2022	10,63 undefined	0,88 undefined	1,11 undefined
2021	8,98 undefined	0,77 undefined	1,00 undefined
2020	8,59 undefined	0,76 undefined	0,86 undefined
2019	9,10 undefined	0,70 undefined	0,81 undefined
2018	8,26 undefined	0,61 undefined	0,73 undefined
2017	7,40 undefined	0,45 undefined	0,62 undefined
2016	8,12 undefined	0,38 undefined	0,55 undefined
2015	9,21 undefined	0,51 undefined	0,59 undefined
2014	9,59 undefined	0,50 undefined	0,48 undefined
2013	8,13 undefined	0,47 undefined	0,48 undefined
2012	6,94 undefined	0,36 undefined	0,60 undefined
2011	5,94 undefined	0,37 undefined	0,33 undefined
2010	4,70 undefined	0,32 undefined	0,40 undefined
2009	3,90 undefined	0,23 undefined	0,35 undefined
2008	3,20 undefined	0,13 undefined	0,24 undefined
2007	3,05 undefined	−0,25 undefined	−0,09 undefined
2006	2,93 undefined	−0,55 undefined	−0,52 undefined
2005	3,40 undefined	0,07 undefined	0,11 undefined
2004	2,86 undefined	0,10 undefined	0,09 undefined

	Omsetning per aksje	EBIT per aksje	Resultat per aksje
2004	2,86 CNY	0,10 CNY	0,09 CNY
2005	3,40 CNY	0,07 CNY	0,11 CNY
2006	2,93 CNY	−0,55 CNY	−0,52 CNY
2007	3,05 CNY	−0,25 CNY	−0,09 CNY
2008	3,20 CNY	0,13 CNY	0,24 CNY
2009	3,90 CNY	0,23 CNY	0,35 CNY
2010	4,70 CNY	0,32 CNY	0,40 CNY
2011	5,94 CNY	0,37 CNY	0,33 CNY
2012	6,94 CNY	0,36 CNY	0,60 CNY
2013	8,13 CNY	0,47 CNY	0,48 CNY
2014	9,59 CNY	0,50 CNY	0,48 CNY
2015	9,21 CNY	0,51 CNY	0,59 CNY
2016	8,12 CNY	0,38 CNY	0,55 CNY
2017	7,40 CNY	0,45 CNY	0,62 CNY
2018	8,26 CNY	0,61 CNY	0,73 CNY
2019	9,10 CNY	0,70 CNY	0,81 CNY
2020	8,59 CNY	0,76 CNY	0,86 CNY
2021	8,98 CNY	0,77 CNY	1,00 CNY
2022	10,63 CNY	0,88 CNY	1,11 CNY
2023	10,69 CNY	1,06 CNY	1,28 CNY
2024e	11,86 CNY	0 CNY	1,57 CNY
2025e	13,01 CNY	0 CNY	1,90 CNY
2026e	14,25 CNY	0 CNY	2,25 CNY

	Antall aksjer
2004	739,30 mill. Aktien
2005	739,30 mill. Aktien
2006	739,30 mill. Aktien
2007	739,30 mill. Aktien
2008	739,30 mill. Aktien
2009	739,30 mill. Aktien
2010	739,30 mill. Aktien
2011	739,30 mill. Aktien
2012	739,30 mill. Aktien
2013	739,30 mill. Aktien
2014	739,30 mill. Aktien
2015	768,90 mill. Aktien
2016	768,90 mill. Aktien
2017	768,90 mill. Aktien
2018	769,40 mill. Aktien
2019	768,90 mill. Aktien
2020	768,90 mill. Aktien
2021	769,14 mill. Aktien
2022	776,39 mill. Aktien
2023	768,87 mill. Aktien
2024e	768,87 mill. Aktien
2025e	768,87 mill. Aktien
2026e	768,87 mill. Aktien

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Utdeling
2026e	1,21 undefined
2025e	1,21 undefined
2024e	1,21 undefined
2023	1,12 undefined
2022	0,50 undefined
2021	0,30 undefined
2020	0,30 undefined
2019	0,22 undefined
2018	0,20 undefined
2017	0,15 undefined
2016	0,25 undefined
2015	0,15 undefined
2014	0,05 undefined
2013	0,10 undefined
2012	0,20 undefined
2011	0,20 undefined
2006	0,08 undefined
2005	0,08 undefined
2004	0,08 undefined

	Utdeling	Utdeling (estimat)
2004	0,08 CNY	0 CNY
2005	0,08 CNY	0 CNY
2006	0,08 CNY	0 CNY
2007	0 CNY	0 CNY
2008	0 CNY	0 CNY
2009	0 CNY	0 CNY
2010	0 CNY	0 CNY
2011	0,20 CNY	0 CNY
2012	0,20 CNY	0 CNY
2013	0,10 CNY	0 CNY
2014	0,05 CNY	0 CNY
2015	0,15 CNY	0 CNY
2016	0,25 CNY	0 CNY
2017	0,15 CNY	0 CNY
2018	0,20 CNY	0 CNY
2019	0,22 CNY	0 CNY
2020	0,30 CNY	0 CNY
2021	0,30 CNY	0 CNY
2022	0,50 CNY	0 CNY
2023	1,12 CNY	0 CNY
2024e	0 CNY	1,21 CNY
2025e	0 CNY	1,21 CNY
2026e	0 CNY	1,21 CNY

Dato	Tianjin Pharmaceutical Da Ren Tang Group Corp Utbetalingsforhold
2026e	37,84 %
2025e	39,64 %
2024e	37,23 %
2023	36,64 %
2022	45,05 %
2021	30,00 %
2020	34,88 %
2019	27,16 %
2018	27,40 %
2017	24,19 %
2016	45,45 %
2015	25,42 %
2014	10,42 %
2013	20,83 %
2012	33,33 %
2011	60,61 %
2010	36,64 %
2009	36,64 %
2008	36,64 %
2007	36,64 %
2006	−14,42 %
2005	68,18 %
2004	83,33 %

	Utbetalingsforhold
2004	83,33 %
2005	68,18 %
2006	−14,42 %
2007	36,64 %
2008	36,64 %
2009	36,64 %
2010	36,64 %
2011	60,61 %
2012	33,33 %
2013	20,83 %
2014	10,42 %
2015	25,42 %
2016	45,45 %
2017	24,19 %
2018	27,40 %
2019	27,16 %
2020	34,88 %
2021	30,00 %
2022	45,05 %
2023	36,64 %
2024e	37,23 %
2025e	39,64 %
2026e	37,84 %

EPS-estimat	EPS-Actual	Rapporteringskvartal
0,22	0,13 (−41,49 %)	2014 Q4
0,18	0,08 (−56,00 %)	2014 Q3
0,15	0,13 (−14,19 %)	2014 Q2
0,21	0,16 (−24,56 %)	2013 Q4
0,14	0,06 (−57,57 %)	2013 Q3
0,13	0,10 (−20,82 %)	2013 Q2

%	Navn	Aksjer	Endring
42,38 %	Tianjin Pharmaceutical Holdings Ltd.	325 855 528	0
1,09 %	Fullgoal Fund Management Co., Ltd.	8 392 119	−340 800
0,70 %	Zhong Ou Asset Management Co., Ltd.	5 348 982	−8 489 300
0,61 %	GF Fund Management Co., Ltd.	4 711 501	−1 989 900
0,57 %	Chen (Shihui)	4 418 118	4 418 118
0,54 %	China Universal Asset Management Co., Ltd.	4 124 015	−422 094
0,31 %	Hotland Innovation Asset Management Co., Ltd.	2 413 803	−230 080
0,29 %	E Fund Management Co. Ltd.	2 252 050	−2 748 720
0,29 %	China Southern Asset Management Co. Ltd.	2 228 492	117 800
0,27 %	ICBC Credit Suisse Asset Management Co. Ltd.	2 107 589	−243 100
0,23 %	Cinda Fund Management Co., Ltd.	1 805 256	−2 020 600
0,22 %	China Asset Management Co., Ltd.	1 722 109	53 900
0,21 %	Bosera Asset Management Co., Ltd.	1 589 300	−30 200
0,20 %	Penghua Fund Management Co., Ltd.	1 510 738	310 800
0,19 %	ZhongRong Fund Mgmt Co., Ltd	1 434 538	−638 862
0,17 %	The Vanguard Group, Inc.	1 311 297	0
0,16 %	JPMorgan Asset Management (China) Company Limited.	1 254 249	1 214 649
0,15 %	China Merchants Fund Management Co. Ltd.	1 153 883	−160 300
0,14 %	Western Leadbank Fund Management Co., Ltd.	1 040 100	1 040 100
0,12 %	CCB Principal Asset Management Co., Ltd.	913 135	103 700
0,11 %	AXA-SPDB Investment Managers Co., Ltd.	813 400	695 400
0,10 %	Harvest Fund Management Co., Ltd.	803 209	−741 615
0,09 %	Guotai Junan Securities Assets Management Co., Ltd.	692 400	692 400
0,09 %	Broad Asset Management Co., Ltd	686 600	686 600
0,08 %	Great Wall Fund Management Co., Ltd.	628 300	−21 700
0,08 %	Tianhong Asset Management Co., Ltd.	579 300	14 300
0,07 %	CITIC Prudential Fund Management Co., Ltd.	560 672	500 000
0,07 %	Zhong Hai Fund Management Co., Ltd.	548 127	548 127
0,06 %	Changsheng Fund Management Co., Ltd.	498 100	−25 400
0,06 %	Morgan Stanley Investment Management (China) Company Limited.	480 200	30 300
0,06 %	Founder Fubon Fund Management Co., Ltd.	460 677	0
0,06 %	Norges Bank Investment Management (NBIM)	458 108	458 108
0,05 %	First-Trust Fund Management Co., Ltd.	388 188	−157 228
0,05 %	Hongde Fund Management Co., Ltd.	349 200	−696 900
0,04 %	Bank of Communications Schroder Fund Management Co., Ltd.	297 773	−5 088 456
0,04 %	Baoying Fund Management Co., Ltd.	273 100	−499 300
0,03 %	Dacheng Fund Management Co., Ltd.	260 201	256 600
0,03 %	Value Partners Ltd.	246 572	−41 400
0,03 %	Maxwealth Fund Management Co., Ltd.	220 000	218 100
0,03 %	Chang Xin Asset Management Co., Ltd.	212 000	−269 200
0,03 %	PengYang Asset Management Co., Ltd	207 000	207 000
0,03 %	Huashang Fund Management Co., Ltd.	200 000	200 000
0,03 %	Dimensional Fund Advisors, L.P.	198 372	−200
0,03 %	Yinhua Fund Management Co., Ltd.	198 031	125 400
0,03 %	Everbright PGIM Fund Management Co., Ltd.	197 000	−179 100
0,02 %	CICC Fund Management Co Ltd.	170 700	−6 500
0,02 %	INVESCO Great Wall Fund Management Co. Ltd.	167 255	−3 200
0,02 %	Wanjia Asset Management Co., Ltd.	167 159	−2 781 983
0,02 %	BOC International (China) Ltd.	142 800	200
0,02 %	Hwabao WP Fund Management Co., Ltd.	116 000	90 000
0,01 %	Huatai-PineBridge Fund Management Co., Ltd.	112 780	−214 603
0,01 %	TongTai Asset Management Co., Ltd.	103 700	103 700
0,01 %	Focusbridge Investments Limited	98 000	98 000
0,01 %	Orient Securities Asset Management Company Limited	95 600	95 600
0,01 %	Handelsbanken Kapitalförvaltning AB	95 500	0
0,01 %	UBS SDIC Fund Management Co., Ltd.	92 800	15 100
0,01 %	BOSC Asset Management Co., Ltd.	87 700	−33 600
0,01 %	Ping An Fund Management Company Limited	77 400	−6 200
0,01 %	ABC-CA Fund Management Co., Ltd.	68 100	−2 897 300
0,01 %	Xinghua Fund Management Co., Ltd.	48 200	48 200
0,01 %	Soochow Asset Management Co., Ltd.	47 200	−34 900
0,01 %	China Fund Management Co., Ltd.	41 600	−28 600
0,01 %	Guotai Asset Management Co., Ltd.	38 700	−445 509
0,00 %	BlackRock Investment Management (UK) Ltd.	38 200	0
0,00 %	SWS MU Fund Management Co., Ltd.	33 300	33 300
0,00 %	JX Asset Management Co., Ltd.	32 078	−84 800
0,00 %	Topsperity Fund Management Co., Ltd.	31 900	22 300
0,00 %	Taikang Asset Management Co., Ltd.	28 100	25 000
0,00 %	CITIC Securities Co., Ltd. (Asset Management)	27 600	27 600
0,00 %	Donghai Funds Management Co., Ltd.	26 800	26 800
0,00 %	Manulife Fund Management Co., Ltd.	25 700	1 000
0,00 %	Sealand Securities Co., Ltd.	23 849	14 349
0,00 %	Zhou (Hong)	23 800	−46 200
0,00 %	Wang (Xin)	23 800	−46 200
0,00 %	Niu (Sheng Fang)	23 800	−46 200
0,00 %	Horizon Asset Management Co., Ltd.	20 700	−4 100
0,00 %	AVIC Fund Management Co., Ltd.	18 700	12 600
0,00 %	Caitong Fund Management Co., Ltd.	18 100	−31 200
0,00 %	China Life AMP Asset Management Co., Ltd	17 200	−300
0,00 %	China Everbright Assets Management, Ltd.	17 000	17 000
0,00 %	HuaAn Fund Management Co., Ltd.	16 900	−1 328 600
0,00 %	Goldstate Capital Fund Management Co., Ltd.	15 000	15 000
0,00 %	CPIC Fund Management Co., Ltd.	14 500	14 500
0,00 %	DBX Advisors LLC.	13 900	13 900
0,00 %	Nykredit Bank AS	13 400	0
0,00 %	Dimensional Fund Advisors, Ltd.	13 000	−6 600
0,00 %	Minsheng Royal Fund Management Company Ltd.	12 200	4 800
0,00 %	Neuberger Berman Fund Management (China) Co., Ltd.	11 739	11 739
0,00 %	Truvalue Asset Management Co., Ltd.	10 500	−1 186 838
0,00 %	Jiao (Yan)	10 200	−19 800
0,00 %	Shanghai Haitong Securities Asset Management Ltd.	10 100	−3 800
0,00 %	Tibet Eastmoney Fund Management Co., Ltd.	9 500	−100
0,00 %	Xingyin Fund Management Co., Ltd.	9 300	9 300
0,00 %	Orient Fund Management Co. Ltd.	9 000	−70 000
0,00 %	Harvest Global Investments Limited	7 162	0
0,00 %	Jyah Asset Management.Co.,LTD	7 000	5 500
0,00 %	Golden Trust Sinopac Fund Management Co., Ltd.	6 500	6 500
0,00 %	Essence Fund Management Co., Ltd.	6 100	−9 400
0,00 %	Everbright Securities Asset Management Co., Ltd.	5 800	−5 900
0,00 %	Northeast Ronghui Securities Asset Management Co., Ltd.	4 900	4 900

Navn	Forhold	Toveukerskorrelasjon	Enmånedskorrelasjon	Trekvartalskorrelasjon	Seksmånederskorrelasjon	Ettårskorrelasjon	Toårig korrelasjon
Citigroup	LeverandørKunde	0,69	-0,04	0,80	0,66	0,43	0,57
GlaxoSmithKline	LeverandørKunde	0,36	-0,43	-0,80	-0,59	-0,42	0,31
Standard Chartered	LeverandørKunde	0,33	0,71	-0,68	-0,32	-0,34	0,26
Tianjin Lisheng Pharm A	LeverandørKunde	0,12	0,91	0,83	0,28	0,17	-0,40
Tianjin Development Hldgs	LeverandørKunde	0,05	-0,58	0,72	0,34	0,18	0,54
DBS Group Holdings	LeverandørKunde	-0,53	-0,72	0,53	0,47	0,02	0,75
ABN AMRO DR	LeverandørKunde	-0,70	-0,75	-0,21	0,60	0,30	0,78

What values and corporate philosophy does Tianjin Pharmaceutical Da Ren Tang Group Corp represent?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy focused on delivering cutting-edge healthcare solutions, the company strives to provide safe and effective pharmaceutical products to improve people's well-being. Tianjin Zhongxin Pharmaceutical Group Corp Ltd's commitment to research and development, along with its dedication to meeting international standards, has positioned the company as a leader in the global pharmaceutical market. Through its emphasis on quality control, continuous improvement, and customer satisfaction, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the delivery of reliable and trustworthy healthcare solutions.

In which countries and regions is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily present?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is primarily present in China.

What significant milestones has the company Tianjin Pharmaceutical Da Ren Tang Group Corp achieved?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd has achieved several significant milestones. It has successfully expanded its product portfolio, notably in the areas of cardiovascular, respiratory, and anti-infective medicines. The company has also secured numerous international certifications, including Good Manufacturing Practice (GMP) certification, ensuring the highest quality standards. Tianjin Zhongxin Pharmaceutical Group Corp Ltd has made remarkable strides in research and development as well, with several innovative drugs being registered and commercialized. Furthermore, the company has established a robust global presence by entering into strategic partnerships and expanding its market reach. These achievements consolidate Tianjin Zhongxin Pharmaceutical Group Corp Ltd's position as a leading player in the pharmaceutical industry.

What is the history and background of the company Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd, a leading pharmaceutical company, has a rich history and background. Established in [year], the company has been dedicated to providing high-quality healthcare products and services to global markets. With a focus on research and development, manufacturing, and marketing, Tianjin Zhongxin has emerged as a trusted name in the pharmaceutical industry. Its commitment to innovation, quality, and customer satisfaction has enabled it to expand its presence both domestically and internationally. Being one of the prominent players in the pharmaceutical market, Tianjin Zhongxin Pharmaceutical Group Corp Ltd continuously strives for excellence through its diverse product portfolio and relentless pursuit of breakthrough solutions in healthcare.

Who are the main competitors of Tianjin Pharmaceutical Da Ren Tang Group Corp in the market?

The main competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd in the market include other leading pharmaceutical companies such as Shanghai Pharmaceuticals Holding Co., Ltd., Sinopharm Group Co., Ltd., Fosun Pharma, and Jiangsu Hengrui Medicine Co., Ltd.

In which industries is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily active?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd primarily operates in the pharmaceutical industry.

What is the business model of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd focuses on the development, production, and sales of pharmaceutical products. As one of the leading pharmaceutical companies in China, Tianjin Zhongxin Pharmaceutical Group Corp Ltd aims to provide high-quality and affordable medications to improve the health and well-being of individuals. With a diverse product portfolio ranging from traditional Chinese medicine to modern pharmaceuticals, the company emphasizes research and innovation to meet the growing healthcare needs of its customers. By adhering to strict quality standards and maintaining a strong distribution network, Tianjin Zhongxin Pharmaceutical Group Corp Ltd ensures the availability and accessibility of its products nationwide.

Hvilken P/E har Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

P/E-forholdet til Tianjin Pharmaceutical Da Ren Tang Group Corp er 20,79.

Hva er P/S-tallet til Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

Tianjin Pharmaceutical Da Ren Tang Group Corp KUV er 2,75.

Hvilken AlleAktien kvalitetsscore har Tianjin Pharmaceutical Da Ren Tang Group Corp?

AlleAktien kvalitetsscore for Tianjin Pharmaceutical Da Ren Tang Group Corp er 7/10.

Hvor høy er omsetningen til Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

forventede Tianjin Pharmaceutical Da Ren Tang Group Corp omsetningen er 9,12 mrd. CNY.

Hvor høy er profitten til Tianjin Pharmaceutical Da Ren Tang Group Corp 2024?

forventede Tianjin Pharmaceutical Da Ren Tang Group Corp -gevinsten er 1,21 mrd. CNY.

Hva gjør Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a Chinese company specialized in the production and sale of pharmaceutical products, health and dietary supplements, and medical devices. Its business model is based on a comprehensive range of products and services that allow it to meet the needs of customers in different markets. The company is divided into several divisions, including the pharmaceutical products division, the dietary supplements division, and the medical devices division. Each of these divisions offers unique products and services tailored to specific needs and requirements. In the field of pharmaceutical products, Tianjin Zhongxin Pharmaceutical Group Corp Ltd manufactures a variety of drugs used to treat various diseases and conditions. This includes antibiotics, anti-inflammatory drugs, cancer medications, as well as treatments for cardiovascular diseases and diabetes. The company also has a research and development department that continuously works on the development of new drugs. The dietary supplements division offers a wide range of products aimed at improving health and well-being. These include vitamins, minerals, enzymes, and herbal extracts. The company adheres to strict standards in the production of its products and uses only high-quality and natural ingredients. The medical devices division of Tianjin Zhongxin Pharmaceutical Group Corp Ltd specializes in the production of medical devices such as blood glucose monitors and blood pressure monitors. These devices are of high quality and comply with all applicable standards and regulations. The business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd also includes collaborations with other companies and organizations around the world. The company has partnerships with a variety of domestic and international companies to expand its product range and strengthen its global presence. Overall, the business model of Tianjin Zhongxin Pharmaceutical Group Corp Ltd is focused on the development, production, and sale of high-quality pharmaceutical products, dietary supplements, and medical devices. Its divisions offer a wide range of products and services tailored to the needs of customers in different markets. Through its global presence and collaborations with other companies and organizations worldwide, the company ensures continuous expansion and future success.

Hvor høy er Tianjin Pharmaceutical Da Ren Tang Group Corp-utbyttet?

Tianjin Pharmaceutical Da Ren Tang Group Corp utbetaler et dividende på 0,50 CNY fordelt over utdelinger i året.

Hvor ofte betaler Tianjin Pharmaceutical Da Ren Tang Group Corp utbytte?

Utbyttet kan for øyeblikket ikke beregnes for Tianjin Pharmaceutical Da Ren Tang Group Corp eller så utdeler ikke selskapet utbytte.

Hva er Tianjin Pharmaceutical Da Ren Tang Group Corp ISIN?

ISIN-en til Tianjin Pharmaceutical Da Ren Tang Group Corp er CNE000001808.

Hva er Tianjin Pharmaceutical Da Ren Tang Group Corp tickeren?

Tikkeren til Tianjin Pharmaceutical Da Ren Tang Group Corp er 600329.SS.

Hvor mye utbytte betaler Tianjin Pharmaceutical Da Ren Tang Group Corp?

I løpet av de siste 12 månedene utbetalte Tianjin Pharmaceutical Da Ren Tang Group Corp et utbytte på 1,12 CNY . Dette tilsvarer en utbytteavkastning på ca. 3,43 %. For de neste 12 månedene vil Tianjin Pharmaceutical Da Ren Tang Group Corp sannsynligvis betale et utbytte på 1,21 CNY.

Hva er utbytterendementet til Tianjin Pharmaceutical Da Ren Tang Group Corp?

Utdelingsrendementet til Tianjin Pharmaceutical Da Ren Tang Group Corp er for øyeblikket 3,43 %.

Når betaler Tianjin Pharmaceutical Da Ren Tang Group Corp utbytte?

Tianjin Pharmaceutical Da Ren Tang Group Corp betaler utbytte kvartalsvis. Dette blir utdelt i månedene , , , .

Hvor sikker er utbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp betalte utbytte hvert år de siste 16 årene.

Hvor høy er utbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp?

For de kommende 12 månedene forventes det utbytter på 1,21 CNY. Dette tilsvarer en utbytteavkastning på 3,70 %.

I hvilken sektor befinner Tianjin Pharmaceutical Da Ren Tang Group Corp seg?

Tianjin Pharmaceutical Da Ren Tang Group Corp tilordnes sektoren 'Helse'.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

For å motta den siste utbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp den på 1,12 CNY, måtte du ha aksjen i porteføljen din før ex-datoen den .

Når betalte Tianjin Pharmaceutical Da Ren Tang Group Corp den siste utbytte?

Utbetalingen av det siste utbyttet fant sted den .

Hvor høy var utbyttet fra Tianjin Pharmaceutical Da Ren Tang Group Corp i år 2023?

I løpet av 2023 ble det utbetalt 0,5 CNY i utbytte fra Tianjin Pharmaceutical Da Ren Tang Group Corp.

I hvilken valuta utbetaler Tianjin Pharmaceutical Da Ren Tang Group Corp utbytte?

Utdelingene fra Tianjin Pharmaceutical Da Ren Tang Group Corp blir betalt ut i CNY.

1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	769,00	861,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	123,00	114,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,00	−56,00
−84,00	−198,00	−353,00	−350,00	−462,00	−536,00	−667,00	−682,00	−493,00	−471,00	−629,00	−611,00	−737,00	−884,00	−1 370,00	−1 547,00	−1 679,00	−1 664,00	−1 816,00	−2 084,00	−2 305,00	−2 068,00	−2 316,00	−2 255,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	−186,00	−191,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−59,00	−93,00	−146,00	−162,00	−180,00	−203,00	−178,00	−198,00	−197,00	−260,00	−254,00	−328,00	−374,00	−424,00	−495,00	−511,00	−505,00	−487,00	−514,00	−554,00	−598,00	−523,00	−496,00	−526,00
69,00	−14,00	157,00	187,00	76,00	10,00	261,00	−28,00	20,00	113,00	83,00	139,00	173,00	20,00	213,00	286,00	360,00	417,00	−4,00	350,00	495,00	671,00	852,00	677,00
−54,00	−79,00	−134,00	−180,00	−589,00	−252,00	−149,00	−63,00	−53,00	−38,00	−86,00	−68,00	−43,00	−41,00	−72,00	−70,00	−92,00	−118,00	−114,00	−175,00	−205,00	−189,00	−156,00	−107,00
74,00	22,00	−67,00	−114,00	−654,00	−109,00	−61,00	120,00	253,00	97,00	22,00	11,00	33,00	22,00	−166,00	102,00	−428,00	86,00	197,00	382,00	−100,00	73,00	−311,00	−12,00
128,00	101,00	66,00	65,00	−65,00	143,00	88,00	184,00	307,00	135,00	108,00	80,00	76,00	63,00	−93,00	172,00	−335,00	204,00	311,00	557,00	104,00	262,00	−154,00	95,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−22,00	−1,00	−244,00	51,00	564,00	114,00	64,00	−51,00	−145,00	−162,00	−49,00	−80,00	5,00	63,00	185,00	−273,00	−367,00	−19,00	−42,00	−10,00	−222,00	0	0	179,00
14,00	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
−83,00	−85,00	54,00	−22,00	505,00	−4,00	−67,00	−187,00	−234,00	−246,00	−86,00	−120,00	−197,00	−75,00	266,00	−491,00	273,00	−339,00	−161,00	−252,00	−370,00	−237,00	−244,00	−236,00
−75,00	−83,00	369,00	22,00	28,00	9,00	5,00	0	0	0	19,00	4,00	1,00	0	239,00	−99,00	784,00	−114,00	8,00	−77,00	25,00	−4,00	−12,00	−29,00
0	0	−69,00	−96,00	−87,00	−128,00	−136,00	−136,00	−89,00	−84,00	−56,00	−45,00	−204,00	−138,00	−157,00	−118,00	−143,00	−205,00	−127,00	−164,00	−173,00	−232,00	−232,00	−387,00
0,27	0,20	0,80	0,75	0,65	0,65	1,24	0,76	0,75	0,81	0,99	1,11	1,30	1,30	2,39	2,24	2,75	2,73	2,36	3,47	3,42	3,77	3,96	3,89
14,80	−93,90	23,70	7,20	−512,60	−241,80	112,10	−91,80	−33,60	75,40	−3,30	70,20	130,90	−20,40	141,00	216,70	268,00	299,60	−118,40	174,30	289,90	482,20	695,45	569,34
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Direkte emisjoner	—
Indirekte utslipp fra innkjøpt energi	—
Indirekte utslipp innenfor verdikjeden	—
CO₂-utslipp	—
CO₂-reduksjonsstrategi	✅
Kullenergi	❌
Atomkraft	❌
Dyretesting	✅
Pelz & Leder	—
Pesticider	—
Palmolje	—
Tobakk	❌
Genteknologi	❌
Klimakonsept	—
Bærekraftig skogbruk	—
Resirkuleringsforskrifter	❌
Miljøvennlig emballasje	❌
Farlige stoffer	❌
Drivstofforbruk og -effektivitet	❌
Vannforbruk og effektivitet	✅

Kvinnelig ansattandel	—
Kvinnelig andel i ledelsen	—
Andel asiatiske ansatte	—
Andel asiatisk ledelse	—
Andel av hispano/latino-ansatte	—
Andel hispano/latino-ledelse	—
Andel svarte ansatte	—
Andel av svart ledelse	—
Andel hvite ansatte	—
Andel hvitt ledelse	—
Voksent innhold	❌
Alkohol	❌
Forsvar	—
Skytevåpen	❌
Hasardspill	❌
Militærkontrakter	❌
Menneskerettighetskonsept	❌
Personvernkonsept	—
Arbeids- og helsevern	✅
katolsk	✅

Bærekraftsrapport	✅
Stakeholder-engasjement	❌
Tilbakeringingspolicy	❌
Konkurranserett	❌

Tianjin Pharmaceutical Da Ren Tang Group Corp Ticker	Tianjin Pharmaceutical Da Ren Tang Group Corp FIGI
600329:CH	BBG000CWRRB4
600329:CG	BBG000CWRRX0
600329:C1	BBG00709HMS7

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
0,29	0,41	0,82	1,52	1,84	2,06	2,12	2,52	2,16	2,26	2,37	2,88	3,47	4,39	5,13	6,01	7,09	7,08	6,24	5,69	6,36	6,99	6,60	6,91	8,25	8,22	9,12	10,00	10,96
-	44,06	99,51	85,04	20,91	12,23	2,47	19,01	−14,02	4,34	4,74	21,78	20,59	26,43	16,81	17,18	17,90	−0,08	−11,84	−8,86	11,76	9,99	−5,58	4,60	19,43	−0,33	10,92	9,66	9,58
49,65	50,49	42,58	37,48	36,81	41,72	45,11	42,55	34,98	34,28	36,91	37,53	37,75	34,84	34,12	31,85	30,27	29,48	32,27	38,67	41,19	41,76	39,07	39,76	39,48	43,66	-	-	-
0,14	0,21	0,35	0,57	0,68	0,86	0,95	1,07	0,76	0,77	0,87	1,08	1,31	1,53	1,75	1,91	2,15	2,09	2,01	2,20	2,62	2,92	2,58	2,75	3,26	3,59	0	0	0
0,03	0,04	0,04	0,06	0,06	0,07	0,07	0,05	−0,41	−0,19	0,09	0,17	0,24	0,27	0,27	0,34	0,37	0,39	0,30	0,35	0,47	0,54	0,59	0,59	0,68	0,81	1,08	1,34	1,65
11,19	9,71	4,50	3,81	3,15	3,54	3,45	2,03	−18,85	−8,19	3,89	5,83	6,80	6,17	5,23	5,72	5,25	5,55	4,73	6,12	7,36	7,66	8,89	8,57	8,26	9,90	11,84	13,36	15,09
0,15	0,11	0,09	0,06	0,09	0,09	0,06	0,08	−0,39	−0,07	0,18	0,26	0,29	0,25	0,44	0,35	0,36	0,45	0,42	0,48	0,56	0,63	0,66	0,77	0,86	0,99	1,21	1,46	1,73
-	−22,45	−24,56	−26,74	34,92	1,18	−25,58	25,00	−582,50	−81,87	−351,43	46,02	14,01	−15,70	78,54	−20,41	1,71	26,33	−6,21	12,53	17,86	11,41	5,76	16,34	11,96	14,52	22,41	20,80	18,72
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
659,30	659,30	659,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	739,30	768,90	768,90	768,90	769,40	768,90	768,90	769,14	776,39	768,87	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Gjør de beste investeringene i ditt liv

Kurs

Kurs

Ticker600329.SS

ISINCNE000001808

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje Omsetning, EBIT, Fortjeneste CNE000001808 ·

Omsetning, fortjeneste & EBIT

Forståelse av omsetning, EBIT og inntekt

Årlig analyse og sammenligninger

Utnytt forventningene for investeringen

Investeringinnsikt

Tianjin Pharmaceutical Da Ren Tang Group Corp Omsetning, fortjeneste og EBIT historikk

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje nøkkeltall

GuV

Omsetning og vekst

Bruttomargin

EBIT og EBIT-margin

Inntekt og vekst

Utestående aksjer

Tolkning av årlig sammenligning

Forventninger og prognoser

Balanse

Forståelse av balansen

Eiendeler

Forpliktelser

Egenkapital

År-for-år analyse

Tolkning av data

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje Marginer CNE000001808 ·

Margen

Forståelse av bruttomarginen

EBIT-marginanalyse

Innsikt i omsetningsmargin

Tolking av forventninger

Sammenlignende analyse

Tianjin Pharmaceutical Da Ren Tang Group Corp Marginhistorikk

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje omsetning, EBIT, fortjeneste per aksje CNE000001808 ·

Omsetning, EBIT og inntjening per aksje

Omsetning per aksje

EBIT per aksje

Inntekt per aksje

Forventede verdier

Tianjin Pharmaceutical Da Ren Tang Group Corp Omsetning, fortjeneste og EBIT per aksje historikk

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje og aksjeanalyse

Tianjin Pharmaceutical Da Ren Tang Group Corp Vurdering etter historisk P/E, EBIT og P/S

Tianjin Pharmaceutical Da Ren Tang Group Corp Antall aksjer CNE000001808 ·

Omsetning, EBIT og inntjening per aksje

Omsetning per aksje

EBIT per aksje

Inntekt per aksje

Forventede verdier

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksjesplitts

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksjeutbytte CNE000001808 ·

Dividende

Oversikt over Dividender

Tolkning og bruk

Investeringsstrategi

Tianjin Pharmaceutical Da Ren Tang Group Corp Utdanningshistorikk

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktiens utbytteandel CNE000001808 ·

Utbetalingsforhold

Hva er den årlige utbetalingsforholdet?

Slik tolker du dataene

Bruk av data for investeringer

Tianjin Pharmaceutical Da Ren Tang Group Corp Utbetalingsforholdshistorikk

Tianjin Pharmaceutical Da Ren Tang Group Corp Resultatestimater

Tianjin Pharmaceutical Da Ren Tang Group Corp Inntektsoverraskelser

Eulerpool ESG Rating for Tianjin Pharmaceutical Da Ren Tang Group Corp-aksjen

Eulerpool World ESG Rating (EESG©)

47/ 100

🌱 Environment

👫 Social

🏛️ Governance

Miljø

Sosial (Social)

Bedriftsstyring (Governance)

Tianjin Pharmaceutical Da Ren Tang Group Corp Aksje Aksjonærstruktur

Tianjin Pharmaceutical Da Ren Tang Group Corp Forsyningskjede

Vanlige spørsmål om Tianjin Pharmaceutical Da Ren Tang Group Corp-aksjen

What values and corporate philosophy does Tianjin Pharmaceutical Da Ren Tang Group Corp represent?

In which countries and regions is Tianjin Pharmaceutical Da Ren Tang Group Corp primarily present?

Ticker
600329.SS

ISIN
CNE000001808